Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05060354 · ClinicalTrials.gov registry record
COVID-19 Vaccine Response in Treated MS Patients
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 159
- Enrollment target
NCT05060354 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 159 participants.
The verdict
NCT05060354 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 159 participants
- Enrollment target
Study Summary
The primary goal of this study is to assess the impact of the two major disease modifying therapy (DMT) classes (B cell therapies and S1P modulators) on humoral and cell-mediated immunity to SARS- CoV-2 vaccination compared to non-MS controls. We have chosen to compare DMT-treated MS patients to non-MS controls because the pivotal vaccine studies were conducted in non-MS healthy control groups in which there is significant clinical data and validated assays for antibody responses.
Interventions
- OTHER Blood draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2021-06-01 |
| Est. Completion | 2023-09-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05060354
The ClinicalTrials.gov registry entry for NCT05060354 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood draw is the first listed.
NCT05060354 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05060354 about?
NCT05060354 is a clinical study titled "COVID-19 Vaccine Response in Treated MS Patients". The primary goal of this study is to assess the impact of the two major disease modifying therapy (DMT) classes (B cell therapies and S1P modulators) on humoral and cell-mediated immunity to SARS- CoV-2 vaccination compared to non-MS controls. We have chosen to compare DMT-treated MS patients to non...
What is the current status of trial NCT05060354?
This trial is currently completed. The enrollment target is 159 participants. The study started on 2021-06-01. Estimated completion is 2023-09-28.
What interventions are being tested in trial NCT05060354?
The interventions under investigation include: Blood draw (OTHER).
Who is sponsoring clinical trial NCT05060354?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.